Results 91 to 100 of about 27,201 (202)

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model

BMC Cancer, 2010
Background There is strong evidence demonstrating that activation of epidermal growth factor receptors (EGFRs) leads to tumor growth, progression, invasion and metastasis.
Collantes Maria, Peñuelas Ivan, Catena Raul, Redrado Miriam, Manrique Irene, Perez-Stable Carlos, Parrondo Ricardo, Nguewa Paul A, Diaz Roque, Díaz-González Juan, Calvo Alfonso   +10 more
doaj   +1 more source

Progress in the Mechanism of Heat Shock Proteins in Gastric Cancer: From Biomarkers to Therapeutic Targets

Immunity, Inflammation and Disease, Volume 14, Issue 10, October 2026.
ABSTRACT Background Gastric cancer remains a major challenge in public health, with low early diagnosis rates and poor prognosis for advanced patients. Heat shock proteins (HSPs) are highly conserved molecular chaperones that maintain proteostasis and promote cell survival under stress.
Wang Yanan, Zhang Jinpeng, Zhou Peng, Wang Yuan, Wang Qingyi, Liang Guoying   +5 more
wiley   +1 more source

Identification of YES1 Inhibitors From Approved Drugs Using a Multimodal Deep Learning Framework

Molecular Informatics, Volume 45, Issue 10, October 2026.
To overcome anti‐HER2 drug resistance, we developed a multimodal deep learning model to identify YES1 inhibitors from approved drugs. By integrating molecular graphs, physicochemical properties, and protein sequence data, our computational screening identified chlorpromazine and raloxifene.
Takayoshi Kawabata, Tatsuaki Takeda, Yuta Tanaka, Soichiro Ushio, Akira Miyamoto, Koki Nakagomi, Tomonori Sakai, Risa Maruyama, Takashi Makita, Hirofumi Hamano, Shinichi Toyooka, Yoshito Zamami   +11 more
wiley   +1 more source

Early‐Phase Research in Pediatric Neuro‐Oncology

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
Jonathan Cunningham
wiley   +1 more source

KYNU in Gastric Cancer Cells Promotes Tumor Progression by Influencing Macrophage Polarization Via PF4

Cancer Science, Volume 117, Issue 10, Page 2676-2692, October 2026.
KYNU is upregulated in gastric cancer cells and activates the PI3K/Akt pathway, leading to PF4 secretion. PF4 drives nonclassical macrophage polarization with high expression of S100A8 and MMP7, which promotes tumor proliferation, migration, and invasion while suppressing phagocytosis, thereby accelerating gastric cancer progression.
Xilun Cui, Changfeng Li, Yuanda Liu, Chang Liu, Wei Yang   +4 more
wiley   +1 more source

Synergistic Efficacy of Dual-Target HSA-Based Delivery for HER and VEGFR Co-Blockade in Triple-Negative Breast Cancer [PDF]

International Journal of Molecular and Cellular Medicine
Resistance to monotherapies targeting receptor tyrosine kinases remains a major challenge in triple‑negative breast cancer (TNBC). Here, we developed a dual‑target HSA‑based nanobioconjugate combining human serum albumin (HSA)‑encapsulated Lapatinib—an ...
Sadegh Rostaminasab, Sahar Memarkashani, tahereh rahdari, Seyed Mohsen Asghari   +3 more
doaj  

Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.

PLoS ONE, 2017
BackgroundOverexpression of human epidermal growth factor receptor 2 (HER2) is observed in approximately 15-23% of breast cancers and these cancers are classified as HER2-positive breast cancer. Trastuzumab is the first-line targeted therapeutic drug for
Tatsuaki Takeda, Hiromasa Yamamoto, Hirotaka Kanzaki, Ken Suzawa, Takahiro Yoshioka, Shuta Tomida, Xiaojiang Cui, Ramachandran Murali, Kei Namba, Hiroki Sato, Hidejiro Torigoe, Mototsugu Watanabe, Kazuhiko Shien, Junichi Soh, Hiroaki Asano, Kazunori Tsukuda, Yoshihisa Kitamura, Shinichiro Miyoshi, Toshiaki Sendo, Shinichi Toyooka   +19 more
doaj   +1 more source

Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer [PDF]

, 2015
Background: Lapatinib alone or in combination with other agents, mostly capecitabine is used for patients with advanced/metastatic HER2 positive breast cancer (HER2+BC) after progression on trastuzumab based therapy.
Rizvi, A., Mahrous, M., Mokhtar, M., Al-Rehaily, S., Darwish, T., Zekri, J., Mansour, M., Karim, S.M., Al-Foheidi, M.   +8 more
core   +1 more source

Phosphorylation of HER receptors relative to tumor and plasma concentrations of lapatinib.

, 2015
Changes (post-/pre-treatment ratios of optical density (OD values)) in EGFR, HER2, and HER3 phosphorylation in response to lapatinib in clinical tumor samples, and their relationship to tumor (left panel) and plasma (right panel) concentrations of ...
Neil L. Spector (523233), Peter Beitsch (827080), Carie L. Kimbrough (827077), Faith C. Robertson (827073), Sarah Bacus (29270), Kelli Glenn (827074), Mark Gittelman (827078), Kevin M. Koch (820458), Kimberly Blackwell (94641), Deborah A. Smith (193779), Leanne Cartee (827075), Jennifer Harris (827076), Eli Avisar (827079)   +12 more
core   +1 more source

Anti-tumor effects of lapatinib on HER2-positive canine prostatic carcinoma cell lines

Open Veterinary Journal
Background: Canine prostatic carcinoma (cPC) is a urogenital tumor with poor prognosis, for which no effective treatment has been established. Recently, it has been shown that human epidermal growth factor receptor type 2 (HER2) is overexpressed in cPC ...
Kenjiro Kaji, Tomohiro Yonezawa, Tomohiro Yonezawa, Yasuyuki Momoi, Shingo Maeda   +4 more
doaj   +1 more source